Takeda Global inquest & evolvement Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug supervision (FDA) touching on the hidden risks associated person with concomitant use of clopidogrel and PPIs.

More: - Read More